{"quote": {"result": [{"language": "en-US", "region": "US", "quoteType": "EQUITY", "typeDisp": "Equity", "triggerable": false, "customPriceAlertConfidence": "LOW", "currency": "CHF", "marketState": "POSTPOST", "exchangeTimezoneShortName": "BST", "gmtOffSetMilliseconds": 3600000, "esgPopulated": false, "regularMarketChangePercent": 0.27130646, "regularMarketPrice": 46.2322, "exchange": "LSE", "shortName": "BASILEA PHARMACEUTICA AG BASILE", "longName": "Basilea Pharmaceutica AG", "messageBoardId": "finmb_1427461", "exchangeTimezoneName": "Europe/London", "market": "gb_market", "regularMarketTime": 1683913505, "regularMarketDayHigh": 46.7, "regularMarketDayRange": "46.15 - 46.7", "regularMarketDayLow": 46.15, "regularMarketVolume": 5009, "regularMarketPreviousClose": 46.10711, "bid": 0.0, "ask": 0.0, "bidSize": 0, "askSize": 0, "fullExchangeName": "LSE", "financialCurrency": "CHF", "regularMarketOpen": 46.3, "averageDailyVolume3Month": 6292, "averageDailyVolume10Day": 11394, "fiftyTwoWeekLowChange": 16.182201, "fiftyTwoWeekLowChangePercent": 0.5385092, "fiftyTwoWeekRange": "30.05 - 55.3", "fiftyTwoWeekHighChange": -9.067799, "fiftyTwoWeekHighChangePercent": -0.16397466, "fiftyTwoWeekLow": 30.05, "fiftyTwoWeekHigh": 55.3, "trailingAnnualDividendRate": 0.0, "trailingAnnualDividendYield": 0.0, "epsTrailingTwelveMonths": -0.585, "sharesOutstanding": 10869600, "bookValue": -1.733, "fiftyDayAverage": 48.01259, "fiftyDayAverageChange": -1.7803879, "fiftyDayAverageChangePercent": -0.03708169, "twoHundredDayAverage": 46.078083, "twoHundredDayAverageChange": 0.15411758, "twoHundredDayAverageChangePercent": 0.0033447049, "marketCap": 4988408, "priceToBook": -26.677553, "sourceInterval": 15, "exchangeDataDelayedBy": 15, "tradeable": false, "cryptoTradeable": false, "firstTradeDateMilliseconds": 1394179200000, "priceHint": 2, "regularMarketChange": 0.12509155, "symbol": "0QNA.L"}], "error": null}, "summary": {"result": [{"assetProfile": {"address1": "Hegenheimermattweg 167b", "city": "Allschwil", "zip": "4123", "country": "Switzerland", "phone": "41 61 606 11 11", "website": "https://www.basilea.com", "industry": "", "sector": "", "longBusinessSummary": "Basilea Pharmaceutica AG, a commercial-stage biopharmaceutical company, focuses on the development of products that address the medical needs in the therapeutic areas of oncology and anti-infectives. It offers Cresemba, an intravenous and oral azole antifungal drug for the treatment of invasive aspergillosis and mucormycosis in the United States, and the European Union, as well as in Phase III clinical trials for invasive fungal infections in Japan. The company also provides Zevtera, an antibiotic for the treatment of community and hospital-acquired pneumonia, as well as in Phase III clinical trials for the treatment of acute bacterial skin and skin structure infections, and Staphylococcus aureus bacteremia. In addition, it engages in developing, a small-molecule inhibitor of DXR, as well as in phase \u00bd clinical trial for urothelial and gastric cancer; and Lisavanbulin, a tumor checkpoint controller drug. Basilea Pharmaceutica AG was founded in 2000 and is headquartered in Allschwil, Switzerland.", "fullTimeEmployees": 141, "companyOfficers": [{"maxAge": 1, "name": "Mr. David  Veitch", "age": 57, "title": "Chief Exec. Officer", "yearBorn": 1965, "fiscalYear": 2022, "totalPay": {"raw": 1198813, "fmt": "1.2M", "longFmt": "1,198,813"}, "exercisedValue": {"raw": 0, "fmt": null, "longFmt": "0"}, "unexercisedValue": {"raw": 0, "fmt": null, "longFmt": "0"}}, {"maxAge": 1, "name": "Mr. Adesh  Kaul", "age": 48, "title": "Chief Financial Officer", "yearBorn": 1974, "exercisedValue": {"raw": 0, "fmt": null, "longFmt": "0"}, "unexercisedValue": {"raw": 0, "fmt": null, "longFmt": "0"}}, {"maxAge": 1, "name": "Dr. Gerrit  Hauck Ph.D.", "age": 58, "title": "Chief Technology Officer", "yearBorn": 1964, "exercisedValue": {"raw": 0, "fmt": null, "longFmt": "0"}, "unexercisedValue": {"raw": 0, "fmt": null, "longFmt": "0"}}, {"maxAge": 1, "name": "Dr. Laurenz  Kellenberger Ph.D.", "age": 55, "title": "Chief Scientific Officer", "yearBorn": 1967, "exercisedValue": {"raw": 0, "fmt": null, "longFmt": "0"}, "unexercisedValue": {"raw": 0, "fmt": null, "longFmt": "0"}}, {"maxAge": 1, "name": "Dr. Marc  Engelhardt M.D.", "age": 58, "title": "Chief Medical Officer", "yearBorn": 1964, "exercisedValue": {"raw": 0, "fmt": null, "longFmt": "0"}, "unexercisedValue": {"raw": 0, "fmt": null, "longFmt": "0"}}, {"maxAge": 1, "name": "Dr. Peer Nils Schroder", "title": "Head of Corp. Communications & Investor Relations", "exercisedValue": {"raw": 0, "fmt": null, "longFmt": "0"}, "unexercisedValue": {"raw": 0, "fmt": null, "longFmt": "0"}}, {"maxAge": 1, "name": "Mr. Damian  Heller", "age": 56, "title": "Gen. Counsel & Corp. Sec.", "yearBorn": 1966, "exercisedValue": {"raw": 0, "fmt": null, "longFmt": "0"}, "unexercisedValue": {"raw": 0, "fmt": null, "longFmt": "0"}}, {"maxAge": 1, "name": "Ms. Ursula  Eberhardt", "age": 60, "title": "Head of Global HR", "yearBorn": 1962, "exercisedValue": {"raw": 0, "fmt": null, "longFmt": "0"}, "unexercisedValue": {"raw": 0, "fmt": null, "longFmt": "0"}}, {"maxAge": 1, "name": "Mr. Mark  Jones", "age": 54, "title": "Head of Project Management & Preclinical Devel.", "yearBorn": 1968, "exercisedValue": {"raw": 0, "fmt": null, "longFmt": "0"}, "unexercisedValue": {"raw": 0, "fmt": null, "longFmt": "0"}}, {"maxAge": 1, "name": "Mr. Peter  Bielmeier Ph.D.", "age": 55, "title": "Head of Global Quality Management", "yearBorn": 1967, "exercisedValue": {"raw": 0, "fmt": null, "longFmt": "0"}, "unexercisedValue": {"raw": 0, "fmt": null, "longFmt": "0"}}], "compensationAsOfEpochDate": 1672444800, "maxAge": 86400}}], "error": null}}